This is a type of medicine used to treat certain cancers. It works by stopping the growth of cancer cells. It's often given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Pemetrexed for Non-Small Cell Lung Cancer?
Pemetrexed is a chemotherapy medicine given by IV infusion to treat two cancers of the chest: non-small cell lung cancer (NSCLC) of the non-squamous type, and pleural mesothelioma, a cancer of the lining around the lungs. The original brand is Alimta; generic versions and a ready-made liquid form sold as Pemfexy contain the same active ingredient. In lung cancer, it is used in several ways. As a first treatment for advanced or metastatic non-squamous NSCLC, it is commonly combined with a platinum chemotherapy (cisplatin or carboplatin) and, for people whose tumors lack EGFR or ALK gene changes, with pembrolizumab (Keytruda), an immunotherapy that helps the immune system attack cancer. It can also be continued alone as maintenance treatment when the cancer has not grown after the first chemotherapy, or used alone when lung cancer returns after earlier chemotherapy. For mesothelioma that cannot be removed with surgery, it is given with cisplatin, and it is also approved as part of a combination with pembrolizumab and platinum chemotherapy. The lung cancer type matters. Pemetrexed has not worked in squamous cell NSCLC and is not used for it, which is one reason tumor testing comes before treatment choices are made.
Cells need folate, a B vitamin, to build new DNA before they divide. Pemetrexed is an antifolate: it looks enough like folate to enter cells and then blocks several folate-dependent enzymes needed to make DNA building blocks. Cancer cells that divide quickly are especially affected, so their growth slows or stops. The same action can reach healthy cells that also divide often, such as those in the bone marrow, which makes blood cells, and the lining of the mouth and gut. That is why low blood counts and mouth sores are among its main side effects, and why the vitamin regimen described below matters.
Pemetrexed is not a pill. It is given into a vein over about 10 minutes at an infusion center, usually once every three weeks (one cycle). The dose is calculated from body size, and the care team adjusts it if blood counts or other side effects require. When given with cisplatin or with pembrolizumab and platinum chemotherapy, the combination typically runs for four or more cycles, and pemetrexed (with or without pembrolizumab) may then continue on its own. Three supporting medicines are part of the treatment, not optional extras. Folic acid is taken by mouth every day, starting about a week before the first infusion and continuing until three weeks after the last. A vitamin B12 injection is given about a week before the first infusion and then every three cycles. These two vitamins substantially lower the risk of severe low blood counts and gut side effects. A steroid, dexamethasone, is taken by mouth twice a day on the day before, the day of and the day after each infusion, also to reduce side effects. Missing these can make treatment harder on the body, so it helps to set reminders and tell the team if a dose was skipped.
Tiredness, nausea and loss of appetite are the most common effects when pemetrexed is given alone. In combinations, vomiting, constipation or diarrhea, mouth sores, rash and low blood counts are also common, partly because of the other medicines. Tiredness often builds over the days after an infusion and may accumulate across cycles. Low blood counts are the main serious risk. A drop in white blood cells makes infections more likely and more dangerous, low platelets cause bleeding or bruising, and low red cells (anemia) cause fatigue and breathlessness. Pemetrexed can also damage the kidneys, especially when vomiting or diarrhea causes dehydration. Less often, it causes a lung inflammation called pneumonitis or a severe blistering skin reaction. Call the oncology team right away for a fever or other signs of infection, unusual bleeding or bruising, urinating much less than usual, new or worsening shortness of breath or a cough that will not go away, blistering or peeling of the skin or inside the mouth, or redness and blisters in an area treated with radiation in the past (a reaction called radiation recall). It helps to know the after-hours number before the first infusion.
Because pemetrexed leaves the body through the kidneys, kidney function is checked with a blood test before every cycle. Pemetrexed is not given when the estimated kidney filtering rate (creatinine clearance) is below 45 mL per minute. People with milder kidney impairment should avoid ibuprofen (Advil, Motrin) for two days before, the day of and two days after each infusion, because it slows the drug's removal and increases side effects. Ask the team before taking other anti-inflammatory pain relievers, and tell them about every prescription, over-the-counter medicine and supplement. Pemetrexed can harm a developing baby. A pregnancy test is done before starting. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and men with partners who could become pregnant should use it for 3 months after the last dose. Breastfeeding should stop during treatment and for 1 week after. Pemetrexed may reduce male fertility, and it is not known whether this recovers, so anyone hoping to have children later may want to discuss sperm banking before starting. People who have had a severe allergic reaction to pemetrexed should not receive it again.
Each treatment day usually starts with blood tests to check blood counts and kidney function; if counts have not recovered enough, the infusion may be delayed or the dose lowered. Extra blood tests may be done between infusions. The infusion itself is short, though combination treatment days take longer. Scans every few cycles show whether the cancer is shrinking, stable or growing. Pemetrexed is used to control advanced cancer and extend life rather than as a stand-alone cure. Results vary widely. As an example of the size of benefit, in a study of maintenance treatment for advanced NSCLC, half of the people given pemetrexed were alive at about 13.4 months, compared with 10.6 months for those given a placebo. Adding pembrolizumab to pemetrexed and platinum chemotherapy improved survival further for people with non-squamous NSCLC. Treatment usually continues as long as it is helping and side effects remain manageable, and it may be stopped or changed if the cancer grows or side effects become too difficult.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Pemetrexed, what you've noticed, or ask the community a question.